vs
Side-by-side financial comparison of Alkermes plc. (ALKS) and Seneca Foods Corp (SENEB). Click either name above to swap in a different company.
Seneca Foods Corp is the larger business by last-quarter revenue ($508.3M vs $384.5M, roughly 1.3× Alkermes plc.). Alkermes plc. runs the higher net margin — 12.8% vs 8.8%, a 4.0% gap on every dollar of revenue. On growth, Seneca Foods Corp posted the faster year-over-year revenue change (1.1% vs -10.6%). Alkermes plc. produced more free cash flow last quarter ($170.0M vs $22.9M). Over the past eight quarters, Seneca Foods Corp's revenue compounded faster (77.1% CAGR vs 4.8%).
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.
Seneca Foods Corporation is an American food processor and distributor headquartered in Fairport, New York, United States. Seneca Foods Corporation conducts its business almost entirely in food packaging, which contributed to about 98% of the company's fiscal year net sales in 2017. Canned vegetables represented 65%, fruit products represented 23%, frozen fruit and vegetables represented 11% and fruit chip products represented 1% of the total food packaging net sales. Non-food packaging sales...
ALKS vs SENEB — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $384.5M | $508.3M |
| Net Profit | $49.3M | $44.8M |
| Gross Margin | 88.0% | 16.4% |
| Operating Margin | 15.1% | 11.8% |
| Net Margin | 12.8% | 8.8% |
| Revenue YoY | -10.6% | 1.1% |
| Net Profit YoY | -66.3% | 205.4% |
| EPS (diluted) | $0.29 | $6.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $384.5M | $508.3M | ||
| Q3 25 | $394.2M | $460.0M | ||
| Q2 25 | $390.7M | $297.5M | ||
| Q1 25 | $306.5M | $345.8M | ||
| Q4 24 | $430.0M | $502.9M | ||
| Q3 24 | $378.1M | $425.5M | ||
| Q2 24 | $399.1M | $304.7M | ||
| Q1 24 | $350.4M | $162.2M |
| Q4 25 | $49.3M | $44.8M | ||
| Q3 25 | $82.8M | $29.7M | ||
| Q2 25 | $87.1M | $14.9M | ||
| Q1 25 | $22.5M | $601.0K | ||
| Q4 24 | $146.5M | $14.7M | ||
| Q3 24 | $92.4M | $13.3M | ||
| Q2 24 | $91.4M | $12.7M | ||
| Q1 24 | $36.8M | — |
| Q4 25 | 88.0% | 16.4% | ||
| Q3 25 | 86.9% | 13.4% | ||
| Q2 25 | 87.3% | 14.1% | ||
| Q1 25 | 83.9% | 4.5% | ||
| Q4 24 | 85.6% | 9.8% | ||
| Q3 24 | 83.3% | 10.1% | ||
| Q2 24 | 84.6% | 14.0% | ||
| Q1 24 | 83.3% | — |
| Q4 25 | 15.1% | 11.8% | ||
| Q3 25 | 22.6% | 9.0% | ||
| Q2 25 | 23.8% | 7.8% | ||
| Q1 25 | 4.5% | 0.6% | ||
| Q4 24 | 37.8% | 5.1% | ||
| Q3 24 | 27.7% | 5.8% | ||
| Q2 24 | 27.5% | 8.3% | ||
| Q1 24 | 12.4% | 2.5% |
| Q4 25 | 12.8% | 8.8% | ||
| Q3 25 | 21.0% | 6.5% | ||
| Q2 25 | 22.3% | 5.0% | ||
| Q1 25 | 7.3% | 0.2% | ||
| Q4 24 | 34.1% | 2.9% | ||
| Q3 24 | 24.4% | 3.1% | ||
| Q2 24 | 22.9% | 4.2% | ||
| Q1 24 | 10.5% | — |
| Q4 25 | $0.29 | $6.48 | ||
| Q3 25 | $0.49 | $4.29 | ||
| Q2 25 | $0.52 | $2.14 | ||
| Q1 25 | $0.13 | $0.10 | ||
| Q4 24 | $0.88 | $2.10 | ||
| Q3 24 | $0.55 | $1.90 | ||
| Q2 24 | $0.53 | $1.80 | ||
| Q1 24 | $0.21 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.6M | $33.3M |
| Total DebtLower is stronger | — | $275.8M |
| Stockholders' EquityBook value | $1.8B | $713.9M |
| Total Assets | $2.5B | $1.2B |
| Debt / EquityLower = less leverage | — | 0.39× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.6M | $33.3M | ||
| Q3 25 | $616.4M | $18.1M | ||
| Q2 25 | $521.2M | $12.1M | ||
| Q1 25 | $399.8M | $42.7M | ||
| Q4 24 | $291.1M | $5.3M | ||
| Q3 24 | $396.3M | $9.5M | ||
| Q2 24 | $535.1M | $5.5M | ||
| Q1 24 | $420.8M | $4.5M |
| Q4 25 | — | $275.8M | ||
| Q3 25 | — | $280.2M | ||
| Q2 25 | — | $293.9M | ||
| Q1 25 | — | $369.9M | ||
| Q4 24 | — | $416.2M | ||
| Q3 24 | — | $504.6M | ||
| Q2 24 | — | $572.1M | ||
| Q1 24 | — | $604.8M |
| Q4 25 | $1.8B | $713.9M | ||
| Q3 25 | $1.7B | $672.9M | ||
| Q2 25 | $1.6B | $644.2M | ||
| Q1 25 | $1.5B | $633.0M | ||
| Q4 24 | $1.5B | $612.8M | ||
| Q3 24 | $1.3B | $598.9M | ||
| Q2 24 | $1.3B | $588.9M | ||
| Q1 24 | $1.3B | $582.9M |
| Q4 25 | $2.5B | $1.2B | ||
| Q3 25 | $2.3B | $1.4B | ||
| Q2 25 | $2.3B | $1.2B | ||
| Q1 25 | $2.1B | $1.2B | ||
| Q4 24 | $2.1B | $1.2B | ||
| Q3 24 | $2.2B | $1.5B | ||
| Q2 24 | $2.2B | $1.4B | ||
| Q1 24 | $2.1B | $1.4B |
| Q4 25 | — | 0.39× | ||
| Q3 25 | — | 0.42× | ||
| Q2 25 | — | 0.46× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.68× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.97× | ||
| Q1 24 | — | 1.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $170.1M | $31.1M |
| Free Cash FlowOCF − Capex | $170.0M | $22.9M |
| FCF MarginFCF / Revenue | 44.2% | 4.5% |
| Capex IntensityCapex / Revenue | 0.0% | 1.6% |
| Cash ConversionOCF / Net Profit | 3.45× | 0.70× |
| TTM Free Cash FlowTrailing 4 quarters | $480.3M | $168.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $170.1M | $31.1M | ||
| Q3 25 | $101.7M | $29.3M | ||
| Q2 25 | $150.2M | $53.7M | ||
| Q1 25 | $98.8M | $91.9M | ||
| Q4 24 | $190.4M | $117.7M | ||
| Q3 24 | $81.6M | $75.5M | ||
| Q2 24 | $146.0M | $50.3M | ||
| Q1 24 | $21.1M | — |
| Q4 25 | $170.0M | $22.9M | ||
| Q3 25 | $84.4M | $21.8M | ||
| Q2 25 | $137.2M | $42.4M | ||
| Q1 25 | $88.7M | $81.4M | ||
| Q4 24 | $180.6M | $108.7M | ||
| Q3 24 | $73.3M | $70.0M | ||
| Q2 24 | $138.9M | $38.3M | ||
| Q1 24 | $12.8M | — |
| Q4 25 | 44.2% | 4.5% | ||
| Q3 25 | 21.4% | 4.7% | ||
| Q2 25 | 35.1% | 14.3% | ||
| Q1 25 | 28.9% | 23.5% | ||
| Q4 24 | 42.0% | 21.6% | ||
| Q3 24 | 19.4% | 16.4% | ||
| Q2 24 | 34.8% | 12.6% | ||
| Q1 24 | 3.6% | — |
| Q4 25 | 0.0% | 1.6% | ||
| Q3 25 | 4.4% | 1.6% | ||
| Q2 25 | 3.3% | 3.8% | ||
| Q1 25 | 3.3% | 3.0% | ||
| Q4 24 | 2.3% | 1.8% | ||
| Q3 24 | 2.2% | 1.3% | ||
| Q2 24 | 1.8% | 4.0% | ||
| Q1 24 | 2.4% | — |
| Q4 25 | 3.45× | 0.70× | ||
| Q3 25 | 1.23× | 0.99× | ||
| Q2 25 | 1.72× | 3.61× | ||
| Q1 25 | 4.40× | 152.87× | ||
| Q4 24 | 1.30× | 8.03× | ||
| Q3 24 | 0.88× | 5.68× | ||
| Q2 24 | 1.60× | 3.98× | ||
| Q1 24 | 0.57× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALKS
| Vivitrol | $124.1M | 32% |
| Aristada And Aristada Initio | $97.2M | 25% |
| LYBALVI | $94.1M | 24% |
| Royalty | $65.7M | 17% |
| Manufacturing Revenue | $3.3M | 1% |
SENEB
| Canned Vegetables | $430.2M | 85% |
| Fruit | $34.6M | 7% |
| Frozen | $29.3M | 6% |
| Manufactured Product Other | $10.8M | 2% |
| Snack | $3.4M | 1% |
